CRBP ▲ +10.9% - Corbus Pharmaceuticals Holdings, Inc. $CRBP - Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity Corbus Pharmaceuticals rose 10.9% on news that the company will host a conference call to discuss topline data from its CANYON-1 clinical trial evaluating CRB-913 for obesity. The announcement of trial readout results typically signals a potential advancement in the company's pipeline and generated investor optimism ahead of the data presentation. 11-SEP-2026 04:01 PM ET